Staedtisches Krankenhaus Kiel GmbH

At Staedtisches Krankenhaus Kiel GmbH, research in Digestive System Diseases focuses on cancers of the stomach and bowel, including gastric cancer, gastroesophageal junction adenocarcinoma, colon cancer, and rectal cancer. These studies are mainly designed to assess new treatment strategies, compare them with current care, and improve outcomes after surgery or in the first-line setting.

• Studies in gastric adenocarcinoma and related upper gastrointestinal cancers are evaluating new combination treatments for better disease control.
• Research in colorectal cancer is examining whether additional therapy can improve disease-free survival after tumor removal.
• Trials in stage II and stage III colon and rectal cancer are exploring ways to refine treatment for patients at higher risk of recurrence.

Overall, this therapeutic area reflects a strong interest in improving both treatment effectiveness and long-term cancer control in digestive tract malignancies.

Clinical research in Hemic and Lymphatic Diseases at this hospital includes myelofibrosis, chronic myelogenous leukemia in chronic phase, acute myeloid leukemia, and relapsed or refractory follicular lymphoma. The trials are aimed at testing new drug combinations, improving response rates, and finding better treatment options for patients whose disease has not responded well to standard therapy.

• Studies in myelofibrosis are assessing whether new combinations can improve symptom control and overall efficacy.
• Research in CML-CP is focused on deepening molecular responses in patients who have already received prior treatment.
• Trials in follicular lymphoma and acute myeloid leukemia are evaluating novel regimens for safety, tolerability, and treatment benefit.

This area highlights the site’s role in advancing therapies for complex blood cancers and related disorders.

Within Neoplasms, the Department of Internal Medicine in Kiel is involved in studies across several solid tumors, including ovarian cancer, small cell lung cancer, and KRAS G12C-mutant non-small cell lung cancer. The research is centered on evaluating new cancer therapies, comparing them with standard treatment, and improving outcomes for patients with advanced or recurrent disease.

• Trials in ovarian and peritoneal cancers are examining whether new maintenance approaches can delay progression.
• Studies in small cell lung cancer and non-small cell lung cancer are testing targeted and combination treatments for better survival and response.
• Research in advanced solid tumors also includes efforts to improve first-line treatment strategies and expand options for difficult-to-treat cancers.

These studies show a broad focus on modern oncology, with attention to both targeted therapy and combination treatment approaches.